title: Intravitreal Ranibizumab for the Treatment of Irvine-Gass Syndrome.
abstract: OBJECTIVE
  The purpose of our study was to evaluate the potential efficacy and safety of intravitreal ranibizumab in patients with pseudophakic cystoid macular edema (CME).
  
  
  METHODS
  This retrospective study comprised 7 eyes with CME treated with intravitreal ranibizumab. Patients were examined at 1 week and 1 month after injection and monthly thereafter. Main outcome measures included changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Safety was assessed by ophthalmic examination and report of systemic adverse effects.
  
  
  RESULTS
  There was a statistically significant difference on BCVA (p < 0.001) and CRT (p < 0.001) before and after the ranibizumab injection. One injection appeared to be sufficient for the resolution of CME, while recurrence was observed in 1 patient, in a long-term follow-up. No observable ocular or systemic side effects were found.
  
  
  CONCLUSIONS
  Intravitreal ranibizumab seems to be effective and safe for the treatment of pseudophakic CME, demonstrating a statistically significant difference in BCVA as well as CRT.
authors.affiliation: 2nd Eye Clinic, "Ophthalmiatrion Athinon" Specialized Eye Hospital , Athens , Greece.
authors.forename: Panagiotis G
authors.initials: PG
authors.lastname: Mitropoulos
authors.forename: Irini P
authors.initials: IP
authors.lastname: Chatziralli
authors.forename: Vasileios G
authors.initials: VG
authors.lastname: Peponis
authors.forename: Evangelos
authors.initials: E
authors.lastname: Drakos
authors.forename: Efstratios A
authors.initials: EA
authors.lastname: Parikakis
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D005260:Female; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification / Q000009:adverse effects; D000069579:Ranibizumab / Q000008:administration & dosage*; D012189:Retrospective Studies; D013577:Syndrome; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab
keywords: Cataract; Irvine-Gass syndrome; cystoid macular edema; phacoemulsification; ranibizumab